Navigation Links
FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD
Date:1/30/2009

First proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation

DEERFIELD, Ill., and OSAKA, Japan, Jan. 30 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX(TM) (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. KAPIDEX (30 mg and 60 mg) is the first proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation designed to provide two separate releases of medication.

"Through the discovery, development and commercialization of new medicines, Takeda has been a leader in acid-related therapy for more than 15 years and is committed to bringing new therapies to market," said Alan MacKenzie, president and CEO, Takeda Pharmaceuticals North America. "KAPIDEX is a new, innovative treatment option in the well-established PPI market."

PPIs work by reducing acid production by turning off many of the acid pumps in the stomach. KAPIDEX contains two types of enteric-coated granules resulting in a concentration-time profile with two distinct peaks: the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. In addition, KAPIDEX can be taken regardless of when food is consumed.

"People with GERD often suffer with heartburn symptoms during the day and night," said David Peura, MD, professor of medicine, University of Virginia Health System. "In the pivotal Phase 3 clinical studies, KAPIDEX demonstrated the ability to provide up to 24-hour heartburn relief with a side effect profile similar to lansoprazole. KAPIDEX, with its DDR formulation, is a new and exciti
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

6

GOOD

Page: 1 2 3 4

Related biology technology :

1. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
2. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
7. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , , Primary efficacy endpoint has been m...nt endometrial cancer, , QUEBEC CITY, Nov. 24...ASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global...erapy and oncology, today announced positive effic...totoxic peptide conjugate, AEZS-108 (formerly AN-1...
(Date:11/24/2009)... , DUBLIN, November 24 /PRNewswire-First...e global specialty biopharmaceutical company, toda...opean Medicines Agency for,velaglucerase alfa, the...nt,for the treatment of Type 1 Gaucher disease. Th...erase alfa that has been submitted, with previous,...
(Date:11/24/2009)... , REDWOOD CITY, Calif., Nov. 24 /PRNewswir...X ) today announced that Randy Scott, Genomic Heal...Annual Piper Jaffray Health Care Conference in New....m. ET. ,, To access the live and subsequently...nvestor Relations section of Genomic Health,s webs...
(Date:11/24/2009)... Program Connects Customers w...les Collected with DNA Genotek Products , ...009 -- DNA Genotek , a leading provider of produc... and preparation, today announced its new global p...ancements for DNA Genotek,s partner community and ...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...esha, Wis. - Supply-chain technology firm RedPrair...tailers who ship directly to consumers or use drop... for rules-based order sourcing called Dlx SourceR... as warehouse, transportation, process and product...companies to create inventory allocation rules bas...
...igh tech is the engine of future economic growth, ...cent study by the California-based Milken Institut...f the risk capital that technology entrepreneurs n...esses. That may soon change thanks to the recent ...yle. , ,Act 255 encourages angel investors and ven...
...anies that do not specialize in software, but inco...ocessors or microcontrollers) into their products,...rotecting that software. The software may not be t...f the product, but a feature nonetheless and a fea...mple, many vehicles, such as motorcycles, trucks a...
Other Biology Technology:An analysis of Wisconsins new venture capital and early stage finance programs 2An analysis of Wisconsins new venture capital and early stage finance programs 3Beyond the screws and gears: Protecting your products by protecting your software 2
(Date:11/26/2009)...stant Staphylococcus Aureus ) and other drug-resi...erature plasma prototype devices have been develop...icidal cocktails. , Two prototype devices have b...ealthy skin (e.g. hands and feet) in hospitals and...reat; and another to shoot bacteria-killing agents...
(Date:11/25/2009)...duced in the stomach, may be used to boost resista...sease, Yale School of Medicine researchers report ...rnal of Neuroscience . , Parkinson,s disease is ... area of the midbrain known as the substantia nigr...Reduced production of dopamine in late-stage Parki...
(Date:11/25/2009)...ighters, police officers and ambulance workers fac...enter complex. They battled to save people from th...tackled fires and evacuated as many people as they...000 people. And making their jobs even harder was ...kers and their relatives jammed mobile networks wi...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Hormone ghrelin can boost resistance to Parkinson's disease 2Magic box for mission impossible 2Magic box for mission impossible 3AUDIO from Medialink and OptumHealth 3A Learn How You Can Save Money on Healthcare this One Time of Year 59101 1A School Assignment That May Add Years to a Childs Life 59096 1A School Assignment That May Add Years to a Childs Life 59096 2A School Assignment That May Add Years to a Childs Life 59096 3BD Ranked in the Top 100 Greenest Big Companies by Newsweek 3B Named Again to Dow Jones Sustainability World and North America Indexes 5311 1BD Ranked in the Top 100 Greenest Big Companies by Newsweek 3B Named Again to Dow Jones Sustainability World and North America Indexes 5311 2
... have a conversation with someone, we not only hea...older or twinkle. Gazes can be direct or shifty. “... meaning to the words we hear. , In a report to be...Autism Research in Seatlle, researchers from UCLA ... They hear and they see, of course, but the areas ...
...ity of Florida researchers have revealed how the i...es and prevents immune cells from reaching the sit...01 when letters containing the bacteria,s spores w...hed last week in the EMBO Journal, may lead to qui...se causes flu-like symptoms that can take weeks to...
...wing premature birth rate in the United States app...of pesticides and nitrates, according to work cond...cal pediatrics at the Indiana University School of...diatric Academic Societies, annual meeting, a comb...the Society for Pediatric Research, the Ambulatory...
Other Biology News:A frown or a smile? Children with autism can't discern 2Anthrax paralyzes immune cells with lethal toxin, UF research shows 2Anthrax paralyzes immune cells with lethal toxin, UF research shows 3Premature births may be linked to seasonal levels of pesticides and nitrates in surface water 2
Rabbit Anti-Human IRF7 Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit Anti-PI3K p110 delta (Poly6049) Polyclonal Antibody, Unconjugated from BioLegend
Rabbit Anti-Human Retinoic Acid-Induced 3 (RAI3 / RAIG1) Polyclonal Antibody, Unconjugated from IMGENEX
Mouse Anti-Human CD164 Antibody, Biotin Conjugated from BioLegend
Biology Products: